Back to results
US 7,396,679 B2Granted
Oncolytic adenovirus
AssigneeOnyx Pharmaceuticals, Inc.
InventorsLeisa Johnson, Ali Fattaey, Terry Hermiston, Yuqiao Shen, Sylvie Laquerre
Life of this patent
Estimating the term…
Abstract
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
Claims16
An adenoviral vector comprising
- (i) an E2F responsive transcriptional nucleotide regulatory binding site that controls the expression of an adenoviral early gene,
- (ii) an endogenous adenoviral E3 region promoter, and
- (iii) a heterologous gene inserted in the E3 region of the adenoviral vector, wherein the heterologous gene is heterolorous to the adenoviral vector and operably linked to the endogenous adenoviral E3 region promoter.
An adenoviral vector comprising
- (i) an adenoviral transcriptional nucleotide regulatory binding site that controls the expression of an adenoviral early gene, wherein the site is inactivated by the insertion of an E2F responsive transcriptional nucleotide regulatory binding site such that the E2F responsive transcriptional nucleotide regulatory binding site controls the expression of the adenoviral early gene,
- (ii) an endogenous adenoviral E3 region promoter, and
- (iii) a heterologous gene inserted in the E3 region of the adenoviral vector, wherein the heterologous gene is heterologous to the adenoviral vector and operably linked to the endogenous adenoviral E3 region promoter and is heterologous to the adenoviral vector.
Dependencies are inferred from the claim text.